Acromegaly
Showing 26 - 50 of 236
Acromegaly Trial in Santa Monica (lanreotide)
Terminated
- Acromegaly
-
Santa Monica, CaliforniaBrain Tumor Center and Pituitary Disorders Program, John Wayne C
Sep 2, 2021
Patients With Associated Somatic Disorders
Completed
- Acromegaly
- Non-interventional cross-sectional survey
-
Moscow, Russian Federation
- +1 more
May 7, 2021
Acromegaly Trial in Worldwide (CAM2029 (octreotide subcutaneous depot), Matching )
Active, not recruiting
- Acromegaly
- CAM2029 (octreotide subcutaneous depot)
- Matching placebo
-
Los Angeles, California
- +62 more
Dec 9, 2022
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at
Recruiting
- Acromegaly
-
Montpellier, FranceUhmontpellier
Apr 22, 2021
The Treatment and Natural History of Acromegaly
Completed
- Acromegaly
- Pituitary Neoplasm
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 24, 2020
Acromegaly - Before and After Treatment
Unknown status
- Acromegaly
- +4 more
-
Aarhus, DenmarkAarhus University Hospital, Department of internal medicine and
Dec 4, 2020
Acromegaly: Patient And Physician Perspectives
Completed
- Acromegaly
-
New Orleans, LouisianaTulane School of Public Health and Tropical Medicine
Oct 27, 2020
Patient Satisfaction Trial in Barcelona (Mindfulness, Control)
Recruiting
- Patient Satisfaction
- Mindfulness
- Control
-
Barcelona, SpainResmini Eugenia
Sep 28, 2020
Acromegaly Trial in United States (Somatuline Autogel (lanreotide acetate), Home administration)
Completed
- Acromegaly
- Somatuline Autogel (lanreotide acetate)
- Home administration
-
La Mesa, California
- +12 more
Nov 4, 2020
Acromegaly, Growth Hormone Deficiency, Pituitary Disease Trial in Boston (Recombinant human growth hormone, Saline)
Completed
- Acromegaly
- +2 more
- Recombinant human growth hormone
- Saline
-
Boston, MassachusettsMassachusetts General Hospital
Aug 31, 2020
Predict Lanreotide-induced Disease Activity Normalization in
Withdrawn
- Acromegaly
- (no location specified)
Jun 1, 2020
Acromegaly, Cardiomyopathies Trial in Shanghai (Empagliflozin)
Recruiting
- Acromegaly
- Cardiomyopathies
-
Shanghai, Shanghai, ChinaHuashan Hospital
Aug 17, 2020
Headache, Pituitary Tumor, Acromegaly Trial (Transcranial magnetic stimulation, Acetaminophen)
Not yet recruiting
- Headache
- +2 more
- Transcranial magnetic stimulation
- Acetaminophen
- (no location specified)
Aug 25, 2020
Acromegaly, Olfactory Disorder Trial in Istanbul (OB volume, CCCRC test)
Completed
- Acromegaly
- Olfactory Disorder
- OB volume
- CCCRC test
-
Istanbul, Fatih, TurkeyBezmialem Vakif University
Mar 13, 2020
Sleep Apnea Syndrome Trial in Grenoble (Diagnosis of acromegaly)
Completed
- Sleep Apnea Syndrome
- Diagnosis of acromegaly
-
Grenoble, Isère, FranceUniversity Hospital Grenoble
Mar 19, 2020
Dynamic Hormone Diagnostics in Endocrine Disease
Unknown status
- Adrenal Insufficiency
- +5 more
- 27 hour subcutaneous fluid sampling
-
Athen, Greece
- +3 more
Aug 3, 2020
Somatostatin Receptors and GH Receptor Expression on Bone of
Completed
- Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
- Trans-sphenoidal surgery
-
Roma, ItalyFondazione Policlinnico Gemelli IRCCS
Apr 6, 2023
Seoul National University Pituitary Disease Cohort Study
Recruiting
- Pituitary Disease
- +7 more
- Dynamic hormone study and Magnetic resonance imaging
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 17, 2020
SAGIT for Classification of Acromegaly in Clinical Practice
Completed
- Acromegaly
- SAGIT
-
Los Angeles, California
- +20 more
Mar 30, 2020
Acromegaly Trial in Munich (lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval)
Completed
- Acromegaly
- lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
-
Munich, GermanyKlinikum Innenstadt
Nov 21, 2019